Frank Yocca, the Chief Scientific Officer of BioXcel Therapeutics, has executed a sale of company stock valued at $7,426. This transaction is part of routine stock management practices often undertaken by executives. The details of the sale were disclosed in a filing with the Securities and Exchange Commission, which is standard procedure for such transactions.
Related Articles
Don't miss out on breaking stories and in-depth articles.